Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Breast Neoplasms 2Stomach Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Penile Squamous Cell Carcinoma (PSCC) 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Metastatic Urothelial Cancer 1Melanoma 1Lymphatic Metastasis 1Gestational Trophoblastic Neoplasias (GTN) 1Endometrial Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 10 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Advanced Solid Tumor 1

Interventions

Magnetic Resonance Spectroscopy 2Indocyanine Green 2sarcolipin 1radium Ra 223 dichloride 1peposertib 1avelumab 1Technetium-99 1Technetium 1Specimen Handling 1Sentinel Lymph Node Biopsy 1Robotic Surgical Procedures 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Radiosurgery 1Optical Imaging 1Nomograms 1Methylation 1Lymph Node Excision 1Gastroenterostomy 1Electroporation 1Drug Therapy 1Conversion to Open Surgery 1Control Groups 1Cisplatin 1Artificial Intelligence 1Ambulatory Surgical Procedures 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphatic Metastasis × avelumab × Clear all
NCT04071236 2026-06-05

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

National Cancer Institute (NCI)

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Lymphatic Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡